<DOC>
	<DOC>NCT00959192</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, in subjects with mild to moderate Alzheimer's disease in Japan.</brief_summary>
	<brief_title>Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Diagnosis of mild to moderate Alzheimer's Disease MiniMental State Examination (MMSE) 1626 Significant Neurological Disease other than Alzheimer's disease Major psychiatric disorder Clinically significant systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>